Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

ClinicalTrials.gov ID

NCT05181735

Lead Sponsor

Groupe Francophone des MyelodysplasiesOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 1Phase 2

Enrollment

150Estimated

Last Update Posted

Mar 5, 2026Actual

Start Date

May 18, 2022Actual

Primary Completion Date

Dec 19, 2028Estimated

Completion Date

Jun 19, 2029Estimated

Official Title

A Randomized Phase I/ II Multicenter Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

Brief Summary

Study of the combination of luspatercept in low-risk myelodysplastic syndrom (LR-MDS) without ring sideroblasts (RS) having failed or being ineligible to ESA

Detailed Description

Part A of the trial=Dose-finding Study: Determination the optimal dose level in terms of both toxicity and efficacy for luspatercept + ESA

Part B : Determination of the superiority and efficacy of the association Luspatercept+ESA (erythroipoiesis Stimulating Agent) over luspatercept alone in patients with lower risk MDS who failed to achieve a response or who subsequently relapsed after ESA, wihtout disease progression

• MDS
• Myelodysplastic Syndromes

• Luspatercept Injection [Reblozyl]
• Eprex

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

Patients must meet all of the following criteria to participate in the study:

• Myelodysplastic syndrome according to current WHO classification

• Age ≥ 18 years

• Patients with lower risk MDS according to IPSS classification (LOW, INT-1) without RS who failed to achieved a response or who subsequently relapse after ESA (at least 60000 U EPO-a over at least 12weeks or equivalent), without disease progression (or ineligible to ESA defined by EPO > 500 UI/l)

• Hemoglobin < 9 gr/dl or Transfusion dependant (at least 3 RBCs in 16 wk in at least 2 transfusion episodes)

• Non del(5q) syndrome

• Adequat renal function, defined by creatinine less than 1.5 times the upper limit of normal, creatinine clearance ≥ 40 mL/min (MDRD formula).

• Adequat liver function, defined by total bilirubin and transaminases less than 1.5 times the upper limit of normal.

• Patient is not known to be refractory to platelet transfusions.

• Written informed consent.

• Patient must understand and voluntarily sign consent form.

• Patient must be able to adhere to the visit schedule as outlined in the study and follow protocol requirements.

• ECOG performance status 0-2 at the time of screening.

• A FCBP (female of childbearing potential) for this study was defined as a sexually mature woman who: (1) had not undergone a hysterectomy or bilateral oophorectomy; or (2) had not been naturally postmenopausal (amenorrhea following cancer therapy did not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months). A FCBP participating in the study must:

  • Have had 2 negative pregnancy tests as verified by the investigator prior to starting IP (unless the screening pregnancy test was done within 72 hours of Cycle 1 Day 1). She must have had agreed to ongoing a monthly pregnancy testing during the course of the study and after EOT
  • If sexually active, agreed to have used, and been able to comply with, highly effective contraception** without interruption, 5 weeks prior to starting IP, during treatment with IP (including dose interruptions), and for 12 weeks after discontinuation of IP.
  • ** Highly effective contraception was defined in this protocol as the following (information also appeared in the ICF): Hormonal contraception (eg, birth control pills, injection, implant, transdermal patch, vaginal ring), intrauterine device, tubal ligation (tying your tubes), or a partner with a vasectomy

• Male subjects must: Have agreed to use a condom, defined as a male latex condom or nonlatex condom NOT made out of natural (animal) membrane (eg, polyurethane), during sexual contact with a pregnant female or a FCBP while participating in the study, during dose interruptions, and for at least 12 weeks following IP discontinuation, even if he had undergone a successful vasectomy

Exclusion Criteria:

A patient meeting any of the following criteria is not eligible to participate in the study:

• Severe infection or any other uncontrolled severe condition.
• Uncontrolled hypertension
• Significant cardiac disease - NYHA Class III or IV or having suffered a myocardial infarction in the last 6 months.
• del(5q) syndrome
• Use of investigational agents within 30 days or any anticancer therapy (including IMiD) within 2 weeks before the study entry with the exception of hydroxyurea. The patient must have recovered at least a grade 1 from all acute toxicity from any previous therapy.
• Use of EPO within 4 weeks before the study entry
• Active cancer, or cancer during the year prior to trial entry other than basal cell carcinoma, or carcinoma in situ of the cervix or breast.
• Patient already enrolled in another therapeutic trial of an investigational drug.
• Known HIV infection or active hepatitis B or C.
• Women who are or could become pregnant or who are currently breastfeeding.
• Any medical or psychiatric contraindication that would prevent the patient from understanding and signing the informed consent form.
• Patient eligible for allogeneic stem cell transplantation.
• Known allergies to luspatercept or EPO or any of its excipients.
• No affiliation to a health insurance system.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Groupe Francophone des MyelodysplasiesOTHER

Collaborators

CelgeneINDUSTRY

bgruson@vivalto-sante.com+33 3 60 12 76 87

sylvain.thepot@chu-angers.fr+33 2 41 35 44 66

benjamin.papoular@ch-argenteuil.fr+33 1 34 23 20 16

bslama@ch-avignon.fr+33 4 32 75 93 94

dmartineau@ch-cotebasque.fr+33 5 59 44 38 32

thorsten.braun@aphp.fr+33 1 48 95 70 51

violainedoncker@gmail.com+33 2 23 21 05 50

MMeunier2@chu-grenoble.fr+33 4 76 76 62 77

altaksin@ght78sud.fr+33 1 39 63 92 60

pirayeh.eftekhari@aphp.fr+33 1 45 21 25 34

klaribi@ch-lemans.fr+33 2 43 43 43 61

f-paul@chu-montpellier.fr+33 4 67 33 22 54

Alice.GARNIER@chu-nantes.fr+33 2 40 08 32 71

jacques.delaunay@groupeconfluent.fr+33 2 28 27 21 16

cluzeau.t@chu-nice.fr+33 4 92 03 58 39

stefan.WICKENHAUSER@chu-nimes.fr+33 4 66 68 40 33

ali.arar@chr-orleans.fr+33 2 38 22 95 46

lionel.ades@aphp.fr+33 1 71 20 70 21

lise.willems@aphp.fr+33 1 58 41 21 20

cecile.bally@aphp.fr+33 1 44 49 53 42

sophie.dimicoli-salazar@chu-bordeaux.fr+33 5 57 65 65 11

claire.calmettes@ch-perigueux.fr+33 5 53 45 25 85

mael.heiblig@chu-lyon.fr+33 4 78 86 22 34

jose-miguel.torregrosa-diaz@chu-poitiers.fr+33 5 49 44 44 44 ext. 45415

riad.benramdane@ght-novo.fr+33 1 30 75 47 41

l.leclech@ch-cornouaille.fr+33 2 98 52 67 31

stanislas.nimubona@chu-rennes.fr+33 2 99 28 42 91

aspasia.stamatoullas@chb.unicancer.fr+33 2 32 08 22 88

Comont.Thibault@iuct-oncopole.fr+33 5 31 15 62 66

emmanuel.gyan@univ-tours.fr+33 2 47 25 87 78

clemence.santana@ch-valence.fr+33 4 75 75 25 92

elena.crisa@ircc.it+390119933096

valeria.santini@unifi.it+39 055 2758020

• Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions

  NCT05384691

  RecruitingInterventionalPhase 2Updated Jan 31, 2024
• A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept

  NCT06971185

  Active, not recruitingObservationalUpdated May 14, 2025
• A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

  NCT06045689

  Active, not recruitingInterventionalPhase 3Updated Jun 15, 2026
• A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States

  NCT06851065

  CompletedObservationalUpdated Feb 17, 2026
• Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.

  NCT05181592

  Active, not recruitingInterventionalPhase 3Updated Sep 30, 2025
• A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

  NCT03682536

  Active, not recruitingInterventionalPhase 3Updated Nov 20, 2024